Immunovant Inc To Discuss Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022 Call Transcript - Thomson StreetEvents

Immunovant Inc To Discuss Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022 Call Transcript

Immunovant Inc To Discuss Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022 Call Transcript - Thomson StreetEvents
Immunovant Inc To Discuss Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022 Call Transcript
Published Jan 05, 2022
13 pages (9235 words) — Published Jan 05, 2022
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of IMVT.OQ conference call or presentation 5-Jan-22 1:00pm GMT

  
Brief Excerpt:

...Operator Good morning. My name is Rob, and I'll serve as your conference call operator. (Operator Instructions) As a reminder, this call is being recorded. Joining me on the call today will be Dr. Pete Salzmann, Chief Executive Officer of Immunovant. Before we begin, I would like to remind everyone that today's conference call will include certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among other things, statements regarding the potential efficacy and safety of Immunovant's product candidate and Immunovant's expectations regarding the timing, design and results of its clinical trials, including the timing of future data readouts and the announcement of future indications. All forward-looking statements are based on estimates and assumptions by Immunovant's management that, although Immunovant believes to be reasonable, are inherently uncertain. All forward-looking statements are subject...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Immunovant Inc
Ticker
IMVT.OQ
Time
1:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

Immunovant Inc To Discuss On Two New Indications For Batoclimab Call Transcript – 2022-09-07 – US$ 54.00 – Edited Transcript of IMVT.OQ conference call or presentation 7-Sep-22 12:00pm GMT

Immunovant Inc Q4 2022 Earnings Call Transcript – 2022-06-08 – US$ 54.00 – Edited Transcript of IMVT.OQ earnings conference call or presentation 8-Jun-22 12:00pm GMT

Immunovant Inc at UBS Global Healthcare Conference Transcript – 2022-05-23 – US$ 54.00 – Edited Transcript of IMVT.OQ presentation 23-May-22 5:15pm GMT

Immunovant Inc To Host R&D Day (Virtual) Transcript – 2022-03-30 – US$ 54.00 – Edited Transcript of IMVT.OQ corporate analyst meeting</ 30-Mar-22 1:00pm GMT

Immunovant Inc at JPMorgan Healthcare Conference (Virtual) Transcript – 2022-01-13 – US$ 54.00 – Edited Transcript of IMVT.OQ presentation 13-Jan-22 2:45pm GMT

Immunovant Inc at Stifel Healthcare Conference (Virtual) Transcript – 2021-11-17 – US$ 54.00 – Edited Transcript of IMVT.OQ presentation 17-Nov-21 7:00pm GMT

Immunovant Inc at Roivant R&D Day (Virtual) Transcript – 2021-09-28 – US$ 54.00 – Edited Transcript of IMVT.OQ presentation 28-Sep-21 8:00pm GMT

Immunovant Inc Q1 2022 Earnings Call Transcript – 2021-08-09 – US$ 54.00 – Edited Transcript of IMVT.OQ earnings conference call or presentation 9-Aug-21 12:00pm GMT

Immunovant, Inc. - Special Call Transcript – 2021-02-02 – US$ 54.00 – Edited Transcript of IMVT.OQ conference call or presentation 2-Feb-21 1:00pm GMT

Immunovant Inc at Credit Suisse Healthcare Conference (Virtual) Transcript – 2020-11-12 – US$ 54.00 – Edited Transcript of IMVT.OQ presentation 12-Nov-20 3:15pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Immunovant Inc To Discuss Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022 Call Transcript" Jan 05, 2022. Alacra Store. May 05, 2024. <http://www.alacrastore.com/thomson-streetevents-transcripts/Immunovant-Inc-To-Discuss-Initiation-of-Phase-3-Trial-for-Batoclimab-in-Myasthenia-Gravis-in-the-First-Half-of-2022-Call-T15082505>
  
APA:
Thomson StreetEvents. (2022). Immunovant Inc To Discuss Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022 Call Transcript Jan 05, 2022. New York, NY: Alacra Store. Retrieved May 05, 2024 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Immunovant-Inc-To-Discuss-Initiation-of-Phase-3-Trial-for-Batoclimab-in-Myasthenia-Gravis-in-the-First-Half-of-2022-Call-T15082505>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.